首頁
Surmodics

7月 2026Surmodics的市場佔有率分析

Surmodics is the recognized industry leader in surface technology for intravascular medical devices. Our high-performance hydrophilic, drug-delivery and hemocompatible coatings are used on market-leading devices in all major intravascular categories.

重工業與工程 > 化學工業

域名surmodics.com

成立年份1979

僱員201 - 500

年度營收$100M - $200M

Surmodics

Surmodics（包含公司地區）

surmodics.com

查看更多網站流量與參與度資訊

Surmodics截至 7月 2026 的總收入為 100M - 200M

Surmodics 熱門網域產生的總收入

Surmodics 熱門網域 3 年內的總收入

Surmodics 熱門網域的總收入

surmodics.com100M - 200M

透過銷售情報查看更多內容

Surmodics的熱門網域總造訪量

了解Surmodics市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

surmodics.com11K

透過銷售情報查看更多內容

Surmodics的熱門網域平均造訪時長

分析Surmodics參與度指標。

過去 3 個月平均造訪時長

子公司細目

surmodics.com00:00:27

透過銷售情報查看更多內容

Surmodics的熱門網域平均頁面瀏覽量

了解Surmodics如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

surmodics.com1.89

透過銷售情報查看更多內容

Surmodics按網域劃分的熱門競爭對手

7月 2026的熱門類似網站，依相似度排名

sawbones.com公司名Sawbones僱員51 - 200總部美國, 華盛頓, Vashon年度營收$15M - $25M訪問總量24.1K健康 > 健康 - 其他

使用的熱門技術Surmodics

这些是Surmodics顶级域名使用的行业网站技术

轉換與分析 (9)

Google Analytics

付費廣告 (3)

DoubleClick

電子郵件服務 (3)

Sendgrid

付款與貨幣 (3)

Cart Functionality

更多技術

13

檢視所有

新聞與訊號來自Surmodics

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Surmodics, Inc. sold assets to Endologix, Inc. on May 20th '26.Santa Rosa, Calif. - May 19, 2026 - Endologix LLC, a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced the acquisition of the Pounce(TM) Thrombectomy System from Surmodics, Inc. The transaction closed on May 18, 2026.

新聞Surmodics, Inc. attended event 23rd Annual VIVA Conference on Nov 3rd '25.Surmodics announces PROWL Registry 160-patient data to be presented in industry-sponsored session at VIVA Conference on November 3.

新聞Surmodics, Inc. attended event 37th Annual TCT Symposium on Oct 29th '25.EDEN PRAIRIE, Minn. - (BUSINESS WIRE) - Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from a sex-specific analysis of 160 real-world acute, subacute, and chronic thrombotic limb ischemia patients from its PROWL registry study were presented by Dr. Peter Monteleone at the 37th Annual TCT Symposium in San Francisco, CA.